Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Investor Presentation (January 2020)

15 slides from Avadel Pharmaceuticals's investor presentation, Jan 10, 2020

  1. Slide 1: Avadel Pharmaceuticals plc Repositioned: Executing New Strategy

    January 2020 1 Avadel Pharmaceuticals plc Repositioned: Executing New Strategy

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation may include forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sec tion 21E of the Securities Exchange Act of 1934. The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and si mil ar expressions,

  3. Slide 3: The New Avadel: All the Ingredients for Success

    AT A GLANCE The New Avadel: All the Ingredients for Success 3 FT218 100% $ 72M > $ 55M a differentiated product with high potential enrolled in pivotal Ph3 study REST - ON, single study required for approval; data readout in Q2 2020 cash, funding well into 2021 including completion of REST - ON tria

  4. Slide 4: The Avadel Story: Repositioned, Executing New Strategy

    THE AVADEL STORY Repositioned, Executing New Strategy. Transformative Next 12 Months Note: 1. Narcolepsy sufferers exhibit excessive daytime sleepiness (EDS) and cataplexy 4 200,000 suffer from narcolepsy 1 in U.S. 2X nightly sodium oxybate 44% non - compliance after 1 year $1.7B sodium oxybate Pivo

  5. Slide 5: Characteristics of Narcolepsy – Serious Disease with Large Unmet Need

    Characteristics of Narcolepsy – Serious Disease with Large Unmet Need ¹Source: GlobalData, June 2018 5 An under - researched and under - diagnosed disease; pathogenesis poorly understood Unmet medical need despite current treatment options Market expected to grow significantly over period to 2027¹ T

  6. Slide 6: A New Paradigm of Treatment is Welcomed by Physicians

    A New Paradigm of Treatment is Welcomed by Physicians 6 “… I don’t know of another medication where the patient has to wake up in the middle of the night to take it again, this is a serious problem for patients that already have a sleep disorder …” Sleep Specialist KOL, Major Academic Hospital Sleep

  7. Slide 7: And Could be Life Changing for Patients

    … And Could be Life Changing for Patients… 7 1X nightly Our Micropump™ delivers one single dose at bedtime “That would be life changing. To not have to get up in the middle of the night, EVERY SINGLE NIGHT. ” – A twice - nightly sodium oxybate patient Life Changing

  8. Slide 8: Leveraging Our Proprietary Micropump Technology

    Leveraging Our Proprietary Micropump™ Technology – Delivering Sodium Oxybate Once Nightly The Advantages • Technology contains thousands of ‘micro particles’ per capsules – each is a miniature delivery system • Microparticulate design can be adapted to each drug’s specific challenges – modify coatin

  9. Slide 9: Powerful Potential Advantages of FT218

    0 20 40 60 80 100 0 2 4 6 8 10 Time (h) GHB Concentration (ug/mL) Mean and Standard Error FT218, n=26 Twice - nightly sodium oxybate, n=27 Mean PK Profiles (6g) Investigational Study Clearly Indicated Powerful Potential Advantages of FT218 The Comparison vs. 2X Nightly The Results Single dose Advant

  10. Slide 10: Overview of the Phase 3 Trial, REST-ON

    Overview of the Phase 3 Trial, REST - ON Pathway • Abbreviated 505(b)(2) approval process; study conducted under SPA agreement with FDA, requires only 1 pivotal study for approval Study Type • Randomized, double - blind, parallel - group placebo - controlled study with 1:1 randomization to FT218 or

  11. Slide 11: Advantage of Legacy Portfolio of Cash Flow Positive Hospital Products

    Advantage of Legacy Portfolio of Cash Flow Positive Hospital Products AKOVAZ ™ BLOXIVERZ ™ VAZCULEP ™ Commercial sterile injectable products used in the hospital setting 2019 annual revenues of $55M+ supporting development of FT218 Nouress ™ (cysteine hydrochloride) sterile injectable approved by FD

  12. Slide 12: Priorities Going Forward

    Priorities Going Forward Laser focus on successful completion of pivotal FT218 Ph3 trial Continue to ensure strong liquidity to support FT218 program – includes maximizing cash flow from Hospital products Scale up FT218 manufacturing and complete NDA requirements 1 . 2 . 3 . Advance FT218 “go to mar

  13. Slide 13: What to Expect: Near-Term Key Milestones

    WHAT TO EXPECT: Near - Term Key Milestones Event Date • Completion of patient enrollment (205) Complete • Nouress PDUFA date Dec 15, 2019 • Nouress launch Pending¹ • Completion of REST - ON study Q1 2020 • REST - ON topline data readout Q2 2020 13 ¹Commercial launch pending resolution of IP matter

  14. Slide 14: The New Avadel: All the Ingredients for Success

    AT A GLANCE The New Avadel: All the Ingredients for Success 14 FT218 100% $ 72M > $ 55M a differentiated product with high potential enrolled in pivotal Ph3 study REST - ON, single study required for approval; data readout in Q2 2020 cash, funding well into 2021 including completion of REST - ON tri

  15. Slide 15: Avadel Pharmaceuticals plc Repositioned: Executing New Strategy

    January 2020 15 Avadel Pharmaceuticals plc Repositioned: Executing New Strategy

Avadel Pharmaceuticals — Investor Presentation (January 2020) on 6ix